Cyclo Therapeutics, Inc. Common Stock

Rafael Holdings has completed its merger with Cyclo Therapeutics, a biotechnology company focused on developing treatments for Niemann-Pick Disease Type C1. The combined company will focus on advancing Cyclo's lead clinical candidate, Trappsol® Cyclo™, which is currently in a Phase 3 trial for NPC1.

Related tickers: CYTH, CYTHW, RFL.

Rafael Holdings reported a net loss for the second quarter and first six months of fiscal year 2025, primarily due to unrealized losses on its investment in Cyclo Therapeutics. The company is focused on Cyclo's lead clinical program Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 following the planned merger with Cyclo Therapeutics.

Related tickers: RFL, CYTH, CYTHW.